scholarly journals Differential expression patterns of estrogen receptor (ER)-β splice variants between papillary thyroid cancer and nodular thyroid goiter

2012 ◽  
Vol 18 (9) ◽  
pp. BR351-BR355 ◽  
Author(s):  
Wenwu Dong ◽  
Jing Li ◽  
Yanhong Huang ◽  
Hao Zhang ◽  
Zhongyan Shan ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Differential Expression ◽  
Papillary Thyroid Cancer ◽  
Splice Variants ◽  
Expression Patterns ◽  
Papillary Thyroid ◽  
Thyroid Goiter

scholarly journals The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Carla Colombo ◽  
Emanuela Minna ◽  
Chiara Gargiuli ◽  
Marina Muzza ◽  
Matteo Dugo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Mirna Expression ◽  
Expression Profiles ◽  
Expression Patterns ◽  
Tissue Type ◽  
Molecular Profile ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Disease Persistence

Abstract Background Papillary thyroid cancer (PTC) is the most frequent endocrine tumor. Radioiodine (RAI) treatment is highly effective in these tumors, but up to 60% of metastatic cases become RAI-refractory. Scanty data are available on either the molecular pattern of radioiodine refractory papillary thyroid cancers (PTC) or the mechanisms responsible for RAI resistance. Methods We analyzed the molecular profile and gene/miRNA expression in primary PTCs, synchronous and RAI-refractory lymph node metastases (LNMs) in correlation to RAI avidity or refractoriness. We classified patients as RAI+/D+ (RAI uptake/disease persistence), RAI−/D+ (absent RAI uptake/disease persistence), and RAI+/D- (RAI uptake/disease remission), and analyzed the molecular and gene/miRNA profiles, and the expression of thyroid differentiation (TD) related genes. Results A different molecular profile according to the RAI class was observed: BRAFV600E cases were more frequent in RAI−/D+ (P = 0.032), and fusion genes in RAI+/D+ cases. RAI+/D- patients were less frequently pTERT mutations positive, and more frequently wild type for the tested mutations/fusions. Expression profiles clearly distinguished PTC from normal thyroid. On the other hand, in refractory cases (RAI+/D+ and RAI−/D+) no distinctive PTC expression patterns were associated with either tissue type, or RAI uptake, but with the driving lesion and BRAF−/RAS-like subtype. Primary tumors and RAI-refractory LNMs with BRAFV600E mutation display transcriptome similarity suggesting that RAI minimally affects the expression profiles of RAI-refractory metastases. Molecular profiles associated with the expression of TPO, SLC26A4 and TD genes, that were found more downregulated in BRAFV600E than in gene fusions tumors. Conclusions The present data indicate a different molecular profile in RAI-avid and RAI-refractory metastatic PTCs. Moreover, BRAFV600E tumors displayed reduced differentiation and intrinsic RAI refractoriness, while PTCs with fusion oncogenes are RAI-avid but persistent, suggesting different oncogene-driven mechanisms leading to RAI refractoriness.

scholarly journals Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer

Oncogene ◽  
2004 ◽  
Vol 23 (44) ◽  
pp. 7436-7440 ◽  
Author(s):  
Milo Frattini ◽  
Cristina Ferrario ◽  
Paola Bressan ◽  
Debora Balestra ◽  
Loris De Cecco ◽  
...  
Keyword(s):  
Gene Expression ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Expression Patterns ◽  
Gene Expression Patterns ◽  
Papillary Thyroid ◽  
Distinct Gene

Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer

Oral Oncology ◽  
2015 ◽  
Vol 51 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Yoon Se Lee ◽  
Yun Sung Lim ◽  
Jin-Choon Lee ◽  
Soo-Geun Wang ◽  
Hee-Young Park ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differential Expression ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Expression Levels

A Postmenopausal Woman with Gross Cystic Disease Fluid Protein-15 and Estrogen Receptor-Positive Recurrence of Papillary Thyroid Cancer

Thyroid ◽  
2010 ◽  
Vol 20 (12) ◽  
pp. 1413-1417 ◽  
Author(s):  
Amanda Winters ◽  
Paul Friedlander ◽  
Bernard M. Jaffe ◽  
Mohamed Abdel Khalek ◽  
Krzysztof Moroz ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Postmenopausal Woman ◽  
Papillary Thyroid Cancer ◽  
Cystic Disease ◽  
Papillary Thyroid ◽  
Positive Recurrence ◽  
Estrogen Receptor Positive ◽  
Cystic Disease Fluid Protein

scholarly journals Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer

2016 ◽  
Vol 5 (4) ◽  
pp. 224-230 ◽  
Author(s):  
Giacomo Sturniolo ◽  
Carles Zafon ◽  
Mariacarla Moleti ◽  
Josep Castellví ◽  
Francesco Vermiglio ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Progesterone Receptor ◽  
Papillary Thyroid Cancer ◽  
Estrogen Receptor Α ◽  
Papillary Thyroid ◽  
Immunohistochemical Expression

scholarly journals Surgical treatment for anaplastic thyroid cancer

2003 ◽  
Vol 11 (3) ◽  
pp. 186-186
Author(s):  
Vladan Zivaljevic ◽  
Aleksandar Diklic ◽  
Ksenija Krgovic ◽  
Milena Kazic ◽  
Nevena Kalezic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Histological Analysis ◽  
Anaplastic Thyroid Cancer ◽  
Fine Needle Biopsy ◽  
Endocrine Surgery ◽  
Papillary Thyroid ◽  
Anaplastic Transformation ◽  
Thyroid Goiter ◽  
Male Patients

Background: Anaplastic thyroid cancer is relatively rare but extremely aggressive neoplasm. The aim of the present paper was to study the possibility of surgery for anaplastic thyroid cancer. Methods: During 5-year period (from 1998 to 2002) in the Center for endocrine surgery, we found anaplastic thyroid cancer in 65 patients (44 female and 21 male patients) of median age 63 years (range: 37-88 years). Diagnosis was determined on the basis of histological analysis in operated patients or on cytology findings in case of patients who were not operated. Histological analysis confirmed anaplastic transformation of papillary thyroid cancer in 18 cases. Results In 50% patients we performed only fine needle biopsy, and in 37% patients operative biopsy or tumor reduction. We performed radical surgery hemithyroidectomy or total thyroidectomy, in 13% patients with anaplastic thyroid cancer. Thyroid goiter was present in 35% patients longer than a year before diagnosis of anaplastic cancer was made. Conclusion: Possibility of surgery for anaplastic thyroid cancer is very limited. In about one third of patients there were longstanding goiter or histological verified dedifferentiation of papillary thyroid cancer. These patients should have been operated before anaplastic transformation.

scholarly journals Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Shucai Yang ◽  
Zhongqin Gong ◽  
Zhimin Liu ◽  
Minghui Wei ◽  
Lingbin Xue ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Cancer Cells ◽  
Papillary Thyroid Cancer ◽  
Estrogen Receptor Alpha ◽  
Peroxisome Proliferator ◽  
Papillary Thyroid ◽  
Peroxisome Proliferator Activated Receptor ◽  
Receptor Alpha ◽  
Induced Apoptosis

PurposeThe inhibition of estrogen receptor alpha (ERα) or the activation of ERβ can inhibit papillary thyroid cancer (PTC), but the precise mechanism is not known. We aimed to explore the role of ERα and ERβ on the production of endogenous peroxisome proliferator-activated receptor gamma (PPARγ) ligands in PTC.Methods2 PTC cell lines, 32 pairs of PTC tissues and matched normal thyroid tissues were used in this study. The levels of endogenous PPARγ ligands 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), 13-S-hydroxyoctadecadienoic acid (13(S)-HODE), and15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) were measured by ELISA.ResultsThe levels of PGJ2 and 15(S)-HETE were significantly reduced in PTC, but 13(S)-HODE was not changed. Activation of ERα or inhibition of ERβ significantly downregulated the production of PGJ2, 15(S)-HETE and 13(S)-HODE, whereas inhibition of ERα or activation of ERβ markedly upregulated the production of these three ligands. Application of endogenous PPARγ ligands inhibited growth, induced apoptosis of cancer cells, and promoted the efficacy of chemotherapy.ConclusionThe levels of endogenous PPARγ ligands PGJ2 and 15(S)-HETE are significantly decreased in PTC. The inhibition of ERα or activation of ERβ can inhibit PTC by stimulating the production of endogenous PPARγ ligands to induce apoptosis in cancer cells.

Sign in / Sign up

Export Citation Format

Share Document